Secretion, bronchial (recent respiratory disorders with difficulty of expectoration) in adults and children over 6 years


Adults and children over 7 years old

600 mg daily in 3 doses, ie 1 sachet 3 times a day.
Children from 6 to 7 years old

400 mg per day, in 2 divided doses, that is 1 sachet twice a day.

The duration of the treatment shall not exceed 5 days without medical advice.

Mode of administration

Oral use.

Deliver the contents of the sachet in a little water.


(R: Respiratory System)

Acetylcysteine ​​is a mucolytic mucoformer. It exerts its action on the gel phase of the mucus, presumably by breaking the bridges, disulfides of the glycoproteins and thus promotes the expectoration

Not applicable.

· History of hypersensitivity to one of the constituents

· Children under 6 years of age (see Warnings and Precautions for Use).

Special warnings

The productive coughs, which represent a fundamental element of broncho-pulmonary defense, must be respected.

The association of mucomodifiers, bronchodilators with antitussives and / or substances, drying (atropinic) secretions is irrational

Mucolytics can induce bronchial overcrowding in infants. Indeed, its capacity for draining bronchial mucus is limited, due to the physiological peculiarities of its respiratory tree. Therefore, they should not be used in infants (see sections Contraindications and adverse effects)

Treatment should be re-evaluated in the event of persistence or aggravation of symptoms or pathology.

This medicinal product contains an azo dye (orange yellow S (E110)) and may cause allergic reactions.
This medicinal product contains lower amounts of ethanol (alcohol), less than 100 mg per sachet-dose.
This medicinal product contains sucrose. Its use is discouraged in patients with fructose intolerance, glucose-galactose malabsorption syndrome or sucrase / isomaltase deficiency

Precautions for use

Caution is advised in patients with peptic ulcers.

This medicinal product contains 1,784 g sucrose per sachet-dose, which must be taken into account in the daily diet in the case of a diet low in sugar, or diabetes.
Not applicable.

Not applicable.

Not applicable.


Studies in the animal have not demonstrated any teratogenic effect. In the absence of teratogenic effect in animals, a malformative effect in the human species is not expected.

Indeed, to date, the substances responsible for malformations in the human species have been shown to be teratogenic in animals in well-conducted studies of two species

In clinical studies, no malformative or fetotoxic effects have occurred to date. However, monitoring of pregnancies exposed to acetylcysteine ​​is insufficient to exclude any risk.

Therefore, the use of acetylcysteine ​​should only be considered during pregnancy if necessary.

There is no data concerning the passage of acetylcysteine ​​in breast milk. However, because of its low toxicity, the potential risks to the child appear negligible when treated with this medication.
As a result, breastfeeding is possible.

· Risk of bronchial over-crowding, especially in the infant and in some patients who are incapable of expectoration, effective (see sections Contraindications and Warnings and Precautions). >

Allergic skin reactions such as pruritus, erythematous rash, urticaria and angioedema

· Possibility of phenomena, intestinal digestive (gastralgia, nausea, diarrhea).

It is then advisable to reduce the dose.

Secretion, bronchial (recent respiratory disorders with difficulty of expectoration) in adults and children over 6 years